Table 3: Comparison of the clinical characteristics of patients who developed CMV reactivation versus those who did not.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Modality** | **Total number**  **210** | **CMV reactivation** | | **P-value** |
| **Yes**  **Number (%)** | **No**  **Number (%)** |
| Age groups  <50 years  ≥50 years | 130 (61.9%)  80 (38.1%) | 25 (19.2%)  12 (15.0%) | 105 (81.5%)  68 (85.0%) | 0.44 |
| Underlying disease  Lymphoma  Multiple myeloma | 115 (55%)  95 (45%) | 23(20.0%)  14(14.7%) | 92(80.0%)  81(85.3%) | 0.32 |
| Stage of the underlying disease  Stage I/II  Stage III/IV  Unknown | 100(48%)  82(39%)  28(13%) | 14(14.0%)  17(20.7%)  6(21.4%) | 86(86.0%)  65(79.3%)  22(78.6%) | 0.23 |
| Lines of chemotherapy before transplantation  ≤ 3 lines  >3 lines  Unknown | 182(86.6%)  25(12%)  3(1.4%) | 33(18.1%)  3(12.0%)  1(33.3%) | 149(81.9%)  22(88.0%)  2(66.7%) | 0.45 |
| Receipt of Bortezomib before transplantation (multiple myeloma only)  Yes  No | 10 (10.5%)  85 (89.5%) | 3 (30%)  11 (12.9%) | 7 (70%)  74 (87.1%) | 0.09 |
| Disease status before transplant  Complete remission  Partial response  Stable disease  Unknown | 34 (16%)  147 (70%)  4 (2%)  25 (12%) | 7 (20.6%)  26 (17.7%)  0  4 (16 %) | 27 (79.4%)  121 (82.3%)  4 (100%)  21 (84%) | 0.59 |
| CMV status before transplant  IgG positive  IgM positive | 205 (97.6%)  10 (5%) | 37(18.0%)  3(30.0%) | 168(82.0%)  7(70.0%) | 0.30  0.29 |
| CMV prophylaxis  Acyclovir  Valacyclovir  Unknown | 198 (94.3)  11 (5.2%)  1 (0.5%) | 27(13.6%)  9(81.8%)  1(100%) | 171(86.4%)  2(18.2%)  0 | < 0.0001 |

CMV: Cytomegalovirus.